Radical prostatectomy for Gleason 3+3 prostate cancer; who, how and why? 
Analysis of the British Association of Urological Surgeons complex operations database.

Joseph John1, John Pascoe1, Sarah Fowler2, Thomas Walton3, Mark Johnson4, Jonathan Aning5, Benjamin Challacombe2,6 and John S McGrath1,2 on behalf of the BAUS Section of Oncology.

1Royal Devon and Exeter NHS Foundation Trust, 2British Association of Urological Surgeons, 3Nottingham University Hospitals NHS Trust, 4Newcastle Upon Tyne Hospitals NHS Foundation Trust, 5North Bristol NHS Trust, 6Guy’s and St Thomas’ NHS Foundation Trust

**Background & objectives**

There is a risk of overtreating low-grade prostate cancer (PCa) with radical prostatectomy (RP). A preference for active surveillance for localised Gleason 3+3 disease was advocated in the 2018 UK National Prostate Cancer Audit. This reflects the peri-operative risks of major pelvic surgery and the common longer-term functional sequelae following RP.

**Objectives**

To understand modern RP practices in England for Gleason 3+3 PCa, describing the patient, indication, procedure, and outcomes.

**Patients and methods**

BAUS manage the complex operations database for RP. Seventy data fields are uploaded by surgical departments, pertaining to patient, disease, surgical, pathological and outcome descriptors. Surgeons can review and amend their data before lockdown and data cleansing. Analysis of all 21,973 RPs recorded in England from 2016-18 was performed to identify 2,627 cases of Gleason 3+3 disease diagnosed pre-operatively.

**Patient / disease description**

- 3+3 patients: 12% of all RPs.
- Median age 63 (IQR 56-68).
- ASA 1-2 in 89%, BMI ≥30 in 21%.
- Median PSA 7.0 (IQR 5.1 – 10.4).
- Primary treatment of cancer: 70%.
- Previous active surveillance: 28%

**Rationale for RP in GS 3+3**

Pre-operatively:

- ≥cT2b and PSA ≥10: 261 (10%)
- ≥cT2b and PSA <10: 618 (24%)
- ≤cT2b and PSA ≥10: 482 (18%)

52% of patients

**Conclusions**

Justifications identified for RP for 3+3 prostate cancer:
- Intermediate / high-risk disease (PSA≥10, ≥T2b)
- Post-op upstaging or upgrading

Further contributory factors not assessed in this dataset:
- Patient preference
- High disease volume (no. cores / max core length)
- MRI suggesting a higher-grade lesion than biopsy
- Prostate capsule proximity

Peri-operative outcome data indicate that RP in this cohort is safe.